MediPharm Applies for NASDAQ

MediPharm Labs has announced that it has filed an application to list on the NASDAQ Stock Market.

MediPharm Labs Corp. (TSX: LABS), a global leader in specialized, research-driven cannabis extraction, distillation and purification, is pleased to announce it has filed an application to list its common shares on the NASDAQ Stock Market (the "NASDAQ"). The Company will continue to maintain the listing of its common shares on the Toronto Stock Exchange under the symbol "LABS".

"We are thrilled to be entering the next phase of growth at MediPharm Labs including cross-listing on the NASDAQ, one of the world's foremost exchanges for emerging markets and technology, such as the burgeoning cannabis sector."

Pat McCutcheon, Chief Executive Officer, MediPharm Labs

McCutcheon went on to say that "listing alongside our peers on the NASDAQ will enhance our visibility and access to a larger base of institutional and retail shareholders in the U.S. and globally." In advance of its anticipated listing on the NASDAQ, MediPharm Labs will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission (the "SEC"). The listing of the Company's common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements, including the SEC declaring the Form 40-F Registration Statement effective. The Company will provide updates on its progress upon receiving final approval.

To learn more about Medipharm Labs, visit their company HQ here.

Disclaimer: Past performance is not an indicator of future performance.

Disclaimer: past performance is not an indicator of future performance.
Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *